Verstovsek, S., Chen, C., Egyed, M., Ellis, M., Fox, L., Goh, Y., . . . Mesa, R. (2021). MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Medicine.
Chicago-čujuhus (17. p.)Verstovsek, S., et al. MOMENTUM: Momelotinib Vs Danazol in Patients with Myelofibrosis Previously Treated with JAKi Who Are Symptomatic and Anemic. Future Medicine, 2021.
MLA-čujuhus (9. p.)Verstovsek, S., et al. MOMENTUM: Momelotinib Vs Danazol in Patients with Myelofibrosis Previously Treated with JAKi Who Are Symptomatic and Anemic. Future Medicine, 2021.
Muitte dárkkistit čujuhemiid riektatvuođa, ovdal go geavahat daid iežat deavsttas.